Akeso Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Akeso ha aumentado sus beneficios a una tasa media anual de 38.1%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 11.7% anual. Los ingresos han ido creciendo a una tasa media de 86.8% al año. La rentabilidad financiera de Akeso es de 43%, y sus márgenes netos son de 44.8%.

Información clave

38.1%

Tasa de crecimiento de los beneficios

63.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	11.0%
Tasa de crecimiento de los ingresos	86.8%
Rentabilidad financiera	43.0%
Margen neto	44.8%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Mar 25

Recent updates

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Apr 24

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Mar 25

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Dec 28

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Nov 16

Is Akeso (HKG:9926) Using Too Much Debt?

Oct 02

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Aug 31

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Mar 21

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Mar 02

Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Aug 28

Is Akeso (HKG:9926) Using Too Much Debt?

Apr 10

Akeso (HKG:9926) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Dec 28

Is Akeso (HKG:9926) Using Too Much Debt?

Sep 05

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Akeso. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SEHK:9926 Ingresos, gastos y beneficios (CNY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	4,526	2,028	1,090	1,254
30 Sep 23	4,439	2,008	1,071	1,278
30 Jun 23	4,351	1,987	1,052	1,302
31 Mar 23	2,595	409	902	1,313
31 Dec 22	838	-1,168	752	1,323
30 Sep 22	549	-1,224	672	1,239
30 Jun 22	260	-1,280	592	1,155
31 Mar 22	243	-1,178	508	1,139
31 Dec 21	226	-1,075	423	1,123
30 Sep 21	177	-1,002	324	1,107
30 Jun 21	129	-929	226	1,091
31 Mar 21	64	-983	240	930
31 Dec 20	0	-1,036	253	769
30 Sep 20	35	-870	197	597
30 Jun 20	71	-703	141	426
31 Mar 20	71	-492	98	367
31 Dec 19	71	-282	55	308
31 Dec 18	3	-142	20	161

Ingresos de calidad: 9926 tiene ganancias de alta calidad.

Margen de beneficios creciente: 9926 pasó a ser rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 9926 ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 38.1% al año.

Acelerando crecimiento: 9926 ha pasado a ser rentable en el último año, lo que dificulta la comparación de la tasa de crecimiento de los beneficios con su promedio de 5 años.

Beneficios vs. Industria: 9926 ha pasado a ser rentable en el último año, lo que es difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (22.1%).

Rentabilidad financiera

Alta ROE: La rentabilidad financiera (43%) de 9926 se considera excepcional.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Akeso Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Recent updates

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Is Akeso (HKG:9926) Using Too Much Debt?

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2023

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Akeso, Inc. Announces China NMPA Approved Anniko (Penpulimab) for First-Line Treatment of Locally Advanced or Metastatic Squamous NSCLC

Now 24% undervalued

Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) Mechanism Shows Promising Antitumor Efficacy and Favorable Safety Profile

Forecast to breakeven in 2023

Less than half of directors are independent

Akeso, Inc. Announces Ivonescimab Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China

Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC

Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022

No longer forecast to breakeven

Akeso's Ivonescimab (PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC

Akeso, Inc. Develops Combination Therapies Based on Its PD-1 BsAbs, Ivonescimab (PD-1/VEGF) in Combination with Drebuxelimab (CD73) Approved for a Clinical Trial on Treating Advanced Solid Tumors

Akeso, Inc. Announces Commencement of Phase Ib/II clinical trial

Forecast to breakeven in 2024

Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Akeso, Inc. Publishes First Approval of Cadonilimab in Drugs, A Peer-Reviewed Medical Journal

Akeso, Inc. to Report First Half, 2022 Results on Aug 23, 2022

Akeso's Cadonilimab (Pd-1/Ctla-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China

Akeso, Inc. Reports Results of Phase IB/II Clinical Trial of Ivonescimab Monotherapy for Advanced Non-Small Cell Lung Cancer Published At the 2022 ASCO Annual Meeting

Akeso, Inc. Announces Oral Presentation Featuring Promising Clinical Data of Cadonilimab (PD-1 CTLA-4 BsABs, AK104) for the First-Line Treatment of R/M Cervical Cancer at ASCO 2022

Akeso, Inc., Annual General Meeting, Jun 28, 2022

Desglose de ingresos y gastos
Beta